{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458274979
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = xi/i
| target = [[CD80]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 357613-77-5
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = S9OX9692ZB
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04295
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}
'''Galiximab''' is a [[monoclonal antibody]] designed for the treatment of [[B-cell lymphoma]]. {{As of|September 2009}}, it is undergoing Phase III [[clinical trial]]s.<ref>[http://www.biogenidec.com/site/pipeline.html Biogen Idec: Pipeline]</ref> The drug is a [[chimeric protein|chimeric]] antibody from ''[[Macaca irus]]'' and ''[[Homo sapiens]]''.<ref>[http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf WHO Drug Information]</ref>

==References==
{{reflist}}

==External links==
* [http://www.biogenidec.com Official website]

{{immunosuppressants}}
{{Monoclonals for immune system}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}